Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shin Nippon Biomedical Laboratories's quarterly Total Liabilities
increased
from Sep. 2025 (円52,751.89 Mil) to Dec. 2025 (円59,873.81 Mil) and
increased
from Dec. 2025 (円59,873.81 Mil) to Mar. 2026 (円61,566.27 Mil).
Shin Nippon Biomedical Laboratories's annual Total Liabilities
increased
from Mar. 2024 (円42,141.72 Mil) to Mar. 2025 (円52,330.92 Mil) and
increased
from Mar. 2025 (円52,330.92 Mil) to Mar. 2026 (円61,566.27 Mil).
Shin Nippon Biomedical Laboratories Total Liabilities Related Terms
Shin Nippon Biomedical Laboratories Total Liabilities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories Total Liabilities Chart
Shin Nippon Biomedical Laboratories Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of 円61,566 Mil mean?
Shin Nippon Biomedical Laboratories (TSE:2395) has a Total Liabilities of 円61,566 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Shin Nippon Biomedical Laboratories and its competitors.
Is Shin Nippon Biomedical Laboratories' Total Liabilities too high?
Shin Nippon Biomedical Laboratories' current Total Liabilities is 円61,566 Mil. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Total Liabilities compare to TMO and DHR?
Shin Nippon Biomedical Laboratories' Total Liabilities of 円61,566 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Diagnostics & Research company?
A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Shin Nippon Biomedical Laboratories and its competitors. Shin Nippon Biomedical Laboratories's current Total Liabilities is 円61,566 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories (TSE:2395) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,783.15, compared to a current price of 円1,279.00 — trading 28.3% below its estimated fair value. The current Total Liabilities is 円61,566 Mil. Shin Nippon Biomedical Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (TSE:2395), the current Total Liabilities is 円61,566 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shin Nippon Biomedical Laboratories (TSE:2395) Overvalued in 2026?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued.
The current stock price of 円1,279.00 is trading 28.3% below its estimated GF Value™ of 円1,783.15.
GuruFocus considers Shin Nippon Biomedical Laboratories to be Modestly Undervalued.
Key valuation signals for TSE:2395:
Total Liabilities: 円61,566 Mil
GF Value™: 円1,783.15 vs. price of 円1,279.00 (28.3% below fair value)
No single metric tells the full story. See the TSE:2395 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shin Nippon Biomedical Laboratories Business Description
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
74GF Score
Get the complete analysis for TSE:2395
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2395 has been successfully added to your 
